MDBriefCase will be unavailable due to maintenance from Sunday, January 14 11PM to Monday, January 15 1AM ET.

2023-03-28

Understanding Swallowing Difficulty: Eosinophilic Esophagitis

Dysphagia or swallowing difficulties can make it challenging to ingest food or beverages. Dysphagia can occur due to health conditions, including stroke, multiple sclerosis, mouth or throat cancer, and gastroesophageal reflux disease (GERD). Inflammatory conditions like eosinophilic esophagitis can also cause it.

Eosinophilic esophagitis (EoE) is a chronic immune disorder that causes inflammation in the esophagus — the tube that carries food from the mouth to the stomach. It can occur when white blood cells or immune cells called eosinophils react to food, allergens, or acid reflux (backflow of stomach acid) in the esophagus. Eosinophils multiply and accumulate in the esophageal lining in response to foreign particles. This causes the esophagus to become inflamed and constricted, leading to swallowing difficulties. 

Eosinophilic esophagitis prevalence has increased over the past 20 years. Approximately five to 10 new cases of eosinophilic esophagitis per 100,000 people emerge every year. In Canada, EoE impacts about 15,000 people. It is more common in adults than children and affects men more than women. 

In Australia, the prevalence of eosinophilic esophagitis was reported to be 1 in 100 adults and 1 in 10,000 children in 2014. With no current data available, anecdotal reports from local gastroenterology experts suggest that the incidence of eosinophilic esophagitis is increasing across Australia. 

What Are the Signs and Symptoms of Eosinophilic Esophagitis?

The primary symptom of eosinophilic esophagitis is inflammation in the esophagus. Other signs and symptoms in adults include the following:

  • Swallowing difficulties
  • Impaction or food getting stuck in the esophagus on swallowing
  • Pain in the center of the chest that does not resolve after taking antacids
  • Regurgitation of backflow of undigested food

Children with eosinophilic esophagitis have similar symptoms. They additionally have difficulty feeding or eating, abdominal pain, and vomiting. EoE in children can lead to poor growth, malnutrition, weight loss, and failure to thrive.

How Is Eosinophilic Esophagitis Diagnosed?

If a patient shows symptoms of eosinophilic esophagitis, the following tests are recommended to diagnose the condition: 

  1. Upper gastrointestinal endoscopy. This gastroenterology test examines the esophagus from the inside. It uses an endoscope — a long, narrow tube with a light and tiny camera — inserted into the esophagus through the mouth to inspect the esophageal lining for swelling or narrowing. 
  2. Biopsy. During endoscopy, you can biopsy the esophagus, removing a small tissue sample, and examine it under a microscope to detect eosinophils.
  3. Esophageal sponge or cytosponge. The test involves swallowing a capsule with a string attached. Once your patient swallows the capsule, it dissolves in the stomach and releases a sponge called a cytosponge. Pull the sponge out of their mouth using the string to collect the esophageal tissue sample. This test acts as a substitute for endoscopy.
  4. Blood tests. You can recommend additional blood tests for your patients to confirm the diagnosis. These can include testing for allergens or allergy-causing substances in the body, eosinophil counts, or antibody levels.

What Does Eosinophilic Esophagitis Treatment Involve?

Eosinophilic esophagitis is a chronic illness that can relapse if patients are not careful. It requires ongoing treatment to manage the symptoms. Eosinophilic esophagitis treatment involves the following:

Diet Therapy

If your patient is diagnosed with eosinophilic esophagitis due to a food allergy, ask them to stop eating the particular food. Avoiding common allergenic foods such as gluten and dairy may reduce inflammation and other eosinophilic esophagitis symptoms. 

Medication

You can prescribe the following medications to ease the symptoms:

  • Proton pump inhibitors such as omeprazole or pantoprazole reduce stomach acid production.
  • Topical steroids such as fluticasone or budesonide reduce inflammation.
  • Monoclonal antibodies such as dupilumab reduce inflammation and allergic responses.

Esophageal Dilation

You can use dilation if a patient’s esophagus is severely constricted or narrowed. Dilating or stretching the esophagus makes swallowing easier and helps avoid continuous medication. 

Lifestyle Changes

If your patient frequently experiences acid reflux or heartburn, you can suggest lifestyle changes to help reduce its frequency. Ask them to avoid foods or drinks that trigger heartburn and to maintain a healthy weight. Also, keeping their head elevated while sleeping can prevent acid reflux.   

What Are the Current Findings on Eosinophilic Esophagitis?

Researchers are currently studying potential therapies to treat eosinophilic esophagitis. 

Some studies show that monoclonal antibodies like RPC4046 and reslizumab help manage eosinophilic esophagitis symptoms. Researchers have found a new monoclonal antibody called AK002 that targets specific receptor molecules on eosinophils and improves symptoms of dysphagia. Another new antibody called CALY-002 can reduce the levels of pro-inflammatory molecules like interleukin 15, which may relieve eosinophilic esophagitis symptoms. 

Additionally, experts are studying the accuracy and efficiency of diagnostic techniques such as the cytosponge to detect eosinophilic esophagitis without endoscopy. 

With further research underway, novel diagnostic tools and targeted therapies can help detect the condition early and resolve symptoms without requiring continuous treatment. 

Learn More With MDBriefCase

Enroll in the course on eosinophilic esophagitis and swallowing difficulties by MDBriefCase to improve your awareness and manage and support your patients better. 

Author Agreement

In submitting your work (the “Work”) for potential posting on the MDBriefCase Healthcare Leadership Lab website (the “Website”), you (“You”) expressly agree to the following:

Review: MDBriefCase is pleased to consider the publication of Your Work on the Website.   The suitability of the Work for posting shall be determined by MDBRiefCase at its sole discretion. Nothing herein shall obligate MDBriefcase to post or otherwise publish the Work, or the maintain its posting in future.   

Editing; Identification: MDBriefcase shall have the right to edit the Work to conform to our standards of style, technological requirements, language usage, grammar and punctuation, provided that the meaning of the Work is not materially altered.  If posted, You will be identified as the author of the Work, or co-author if applicable.  

Grant of Rights:  As a condition of publication and for no monetary compensation, You hereby grant to MDBriefCase the following rights to the Work in any and all media whether now existing or hereafter developed, including print and electronic/digital formats:  (1) the exclusive right of first publication worldwide;  (2) the perpetual non-exclusive worldwide right to publish, reproduce, distribute, sell, adapt, perform, display, sublicense, and create derivative works, alone or in conjunction with other materials; (3) the perpetual non-exclusive worldwide right to use the Work, or any part thereof, in any other publication produced by MDBriefCase and/or on MDBriefCase’s website; and (4) the perpetual non-exclusive worldwide right to use the Work to promote and publicize MDBriefCase or its publications.  The grant of rights survives termination or expiration of this Agreement.    

Warranty:  You warrant that the Work is original with You and that it is not subject to any third party copyright; that You have authority to grant the rights in this Agreement; that publication of the Work will not libel anyone or infringe on or invade the rights of others; that You have full power and authority to enter into this Agreement; that the Work has not been published elsewhere in whole or in part; and that You have obtained permission from the copyright owner consistent with this Agreement for any third party copyrighted material in the Work.  This warranty survives termination or expiration of this Agreement.

Submission Agreement

Thank you for your interest in writing an article for the MDBriefCase Healthcare Leadership Lab website.

Audience and Appropriate Topics

The  Healthcare Leadership Lab welcomes submissions on all topics relevant to leaders in healthcare. Our topics include Leading in Healthcare, Leadership Lessons from COVID-19 and others. We prioritize stories that provide leadership advice to executives and managers in healthcare companies, offer actionable strategies for executing successful projects, and provide interesting angles on current healthcare topics. Submissions must be original work of the authors and unpublished.  When submitting, authors represent that they have included no material that is in violation of the rights of any other person or entity.

Parameters

Articles must be educational and non-promotional. If they mention the author’s company or any of the company’s products or services by name within the text, such mention should be very limited and used for reference only, not for promotion. (For example, an author might cite a survey conducted by his company but not describe his company’s product as a solution to a business problem.) Articles will be edited for clarity, style and brevity. The final headline is determined by the editor.

Length of Submissions

Guest articles for the MDBriefCase Healthcare Leadership Lab may run between 500 and 1000 words. 

Review

MDBriefCase reserves the right to accept or reject any submission  and the right to condition acceptance upon revision of material to conform to its criteria.   

No Compensation

There is no payment for contributed articles. However, MDBriefCase will give the author a byline. Authors are invited to link to the article on personal  websites, corporate websites and social media platforms.

Author Agreements

Each author understands and agrees that any submission accepted for posting is provided subject to MDBriefCase’s Author Agreement